Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Dinesh Khanna^*, Christopher P. Denton, Angelika Jahreis, Jacob M. van Laar, Tracy M. Frech, Marina E. Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Janet E. Pope, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Robert Lafyatis, Giuseppina Stifano, Helen Spotswood, Haiyin Chen-Harris, Sebastian DziadekAlyssa Morimoto, Thierry Sornasse, Jeffrey Siegel, Daniel E. Furst

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Rheumatologie und klinische Immunologie

University of Michigan
University College London
Genentech Incorporated
Utrecht University
University of Utah
University of Liverpool
McGill University
Center for Clinical Sciences Research
Eberhard Karls Universität Tübingen
University of Connecticut Health Center
Universität Paris V
Georgetown University
Justus-Liebig-Universität Gießen
Boston University School of Medicine
Roche Products Ltd
Pharma Research and Early Development (pRED)
University of California, Los Angeles

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Fingerprint

Medicine and Dentistry

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology